BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 27753609)

  • 21. Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis.
    Jiang Y; Zhao M; Tang W; Zheng X
    BMC Cancer; 2024 Feb; 24(1):188. PubMed ID: 38336718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
    Coens C; van der Graaf WT; Blay JY; Chawla SP; Judson I; Sanfilippo R; Manson SC; Hodge RA; Marreaud S; Prins JB; Lugowska I; Litière S; Bottomley A
    Cancer; 2015 Sep; 121(17):2933-41. PubMed ID: 26033286
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of the Taiwan Chinese version of the EORTC QLQ-CR29 to assess quality of life in colorectal cancer patients.
    Shen MH; Chen LP; Ho TF; Shih YY; Huang CS; Chie WC; Huang CC
    BMC Cancer; 2018 Apr; 18(1):353. PubMed ID: 29606101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma.
    Choueiri TK; Tomczak P; Park SH; Venugopal B; Symeonides S; Hajek J; Ferguson T; Chang YH; Lee JL; Haas N; Sawrycki P; Sarwar N; Gross-Goupil M; Thiery-Vuillemin A; Mahave M; Kimura G; Perini RF; Saretsky TL; Bhattacharya R; Xu L; Powles T
    Oncologist; 2024 Feb; 29(2):142-150. PubMed ID: 37589219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-reported outcomes and health-related quality of life for cetuximab versus bevacizumab in metastatic colorectal cancer: a prospective cohort study.
    Marques RP; Heudtlass P; Pais HL; Quintela A; Martins AP
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1719-1728. PubMed ID: 31037398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
    Aranda E; García-Alfonso P; Benavides M; Sánchez Ruiz A; Guillén-Ponce C; Safont MJ; Alcaide J; Gómez A; López R; Manzano JL; Méndez Ureña M; Sastre J; Rivera F; Grávalos C; García T; Martín-Valadés JI; Falcó E; Navalón M; González Flores E; Ma García Tapiador A; Ma López Muñoz A; Barrajón E; Reboredo M; García Teijido P; Viudez A; Cárdenas N; Díaz-Rubio E;
    Eur J Cancer; 2018 Sep; 101():263-272. PubMed ID: 30054049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data.
    Bordeleau L; Szalai JP; Ennis M; Leszcz M; Speca M; Sela R; Doll R; Chochinov HM; Navarro M; Arnold A; Pritchard KI; Bezjak A; Llewellyn-Thomas HA; Sawka CA; Goodwin PJ
    J Clin Oncol; 2003 May; 21(10):1944-51. PubMed ID: 12743147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.
    Wallwiener M; Matthies L; Simoes E; Keilmann L; Hartkopf AD; Sokolov AN; Walter CB; Sickenberger N; Wallwiener S; Feisst M; Gass P; Fasching PA; Lux MP; Wallwiener D; Taran FA; Rom J; Schneeweiss A; Graf J; Brucker SY
    J Med Internet Res; 2017 Sep; 19(9):e322. PubMed ID: 28912116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review.
    Ganesh V; Agarwal A; Popovic M; Cella D; McDonald R; Vuong S; Lam H; Rowbottom L; Chan S; Barakat T; DeAngelis C; Borean M; Chow E; Bottomley A
    Support Care Cancer; 2016 Aug; 24(8):3661-8. PubMed ID: 27193118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health-related quality of life in patients with advanced colorectal cancer: a predictive nomogram including BMI, sex and age.
    Formica V; Nardecchia A; Morelli C; Lucchetti J; Giuliano G; Renzi N; Gallo C; Pellegrino R; Massimiliani V; Serci C; Russo A; Patrikidou A; Arkenau HT; Maiorino L; Tesauro M; Roselli M
    Ann Palliat Med; 2021 Apr; 10(4):4252-4261. PubMed ID: 33832305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
    Long GV; Atkinson V; Ascierto PA; Robert C; Hassel JC; Rutkowski P; Savage KJ; Taylor F; Coon C; Gilloteau I; Dastani HB; Waxman IM; Abernethy AP
    Ann Oncol; 2016 Oct; 27(10):1940-6. PubMed ID: 27405322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of EORTC quality of life core questionnaire (EORTC-QLQ-C30) and gastrointestinal quality of life index (GIQLI) in patients undergoing elective colorectal cancer resection.
    Schwenk W; Neudecker J; Haase O; Raue W; Strohm T; Müller JM
    Int J Colorectal Dis; 2004 Nov; 19(6):554-60. PubMed ID: 15205989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
    Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
    BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
    Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
    Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer.
    Derksen JWG; Kurk SA; Peeters PHM; Dorresteijn B; Jourdan M; van der Velden AMT; Nieboer P; de Jong RS; Honkoop AH; Punt CJA; Koopman M; May AM
    J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):919-928. PubMed ID: 32107889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).
    Nakayama G; Mitsuma A; Sunagawa Y; Ishigure K; Yokoyama H; Matsui T; Nakayama H; Nakata K; Ishiyama A; Asada T; Umeda S; Ezaka K; Hattori N; Takami H; Kobayashi D; Tanaka C; Kanda M; Yamada S; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
    Oncologist; 2018 Aug; 23(8):919-927. PubMed ID: 30049885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients.
    Grande GE; Farquhar MC; Barclay SI; Todd CJ
    Palliat Support Care; 2009 Sep; 7(3):289-97. PubMed ID: 19788770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.
    Schadendorf D; Dummer R; Hauschild A; Robert C; Hamid O; Daud A; van den Eertwegh A; Cranmer L; O'Day S; Puzanov I; Schachter J; Blank C; Salama A; Loquai C; Mehnert JM; Hille D; Ebbinghaus S; Kang SP; Zhou W; Ribas A
    Eur J Cancer; 2016 Nov; 67():46-54. PubMed ID: 27596353
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quality of life of colorectal cancer survivors in a Ghanaian population.
    Yorke J; Acheampong E; Batu EN; Obirikorang C; Yeboah FA; Asamoah EA
    BMC Res Notes; 2019 Nov; 12(1):781. PubMed ID: 31783908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.